Zoledronic acid and renal toxicity: Data from French adverse effect reporting database

Annals of Pharmacotherapy

Volumn 39, Issue 7-8, 2005, Pages 1194-1197

  Munier, Aline ^a   Gras, Valerie ^a   Andrejak, Michel ^a   Bernard, Nathalie ^b   Jean Pastor, Marie Josephe ^c   Gautier, Sophie ^d   Biour, Michel ^e   Massy, Ziad ^a  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b HOSPICES CIVILS DE LYON   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e HÔPITAL SAINT ANTOINE   (France)

Author keywords

Bisphosphonates: Nephrotoxicity; Tubular necrosis; Zoledronic acid

Indexed keywords

ZOLEDRONIC ACID;

ACUTE KIDNEY FAILURE; ADULT; ADVANCED CANCER; AGED; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; DIABETES MELLITUS; FEMALE; FRANCE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MALE; METASTASIS; MULTIPLE MYELOMA; NEPHROTOXICITY; PRIORITY JOURNAL; RISK FACTOR;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; BONE RESORPTION; DATABASES, FACTUAL; DIPHOSPHONATES; FEMALE; FRANCE; HUMANS; IMIDAZOLES; KIDNEY DISEASES; KIDNEY FAILURE, ACUTE; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; NEOPLASMS;

EID: 21744455759     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E589     Document Type: Article

References (12)

1. Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001;19:558-67.
2. Wellington K, Goa KL. Zoledronic acid: a review of its use in the management of bone metastases and hypercalcemia of malignancy. Drugs 2003;63:417-37.
3. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003;9:2643-58.
4. van Beek ER, Cohen LH, Leroy IM, Ebetino FH, Lowik CW, Papapoulos SE. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 2003;33:805-11.
5. Chang JT, Green L, Beitz J. Renal failure with use of zoledronic acid. N Engl J Med 2003;349:1676-8.
6. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
7. Skerjanec A, Berenson J, Hsu C, Major P, Miller WH Jr, Ravera C, et al. The pharmacokinetics and pharraacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol 2003;43:154-62.
8. Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003;64:281-9.
9. Hirschberg R. Nephrotoxicity of third-generation, intravenous bisphosphonate. Toxicology 2004;196:165-7.
10. Smetana S, Michlin A, Rosenman E, Biro A, Boaz M, Katzir Z. Pamidronate-induced nephrotoxic tubular necrosis: a case report. Clin Nephrol 2004;61:63-7.
11. Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D. Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity. Am J Kidney Dis 2003;41:1-6.
12. Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR, Jagannath S, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001;12:1164-72.